A Canadian meta-analysis presented at the ACG Annual Scientific Meeting suggests infliximab may be more effective at inducing remission than adalimumab for patients with ulcerative colitis. Both anti-tumor necrosis factor drugs are FDA-approved for treating ulcerative colitis in patients who do not respond to or tolerate conventional therapy.

Related Summaries